Superworth

Protalix BioTherapeutics PE ratio PLX

Share price divided by earnings per share over the last twelve months, since 2017.

Today, Oct 23, 2026
11.1×
10-year median
34.2×
Against its 10-year history
8th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.1× to 150×
Peer median
21.4×

Protalix BioTherapeutics' PE ratio is 11.1× as of Oct 23, 2026: a share price of $2.55 against $0.23 of earnings per share over the last twelve months.

That is below its ten-year median of 34.2×, lower than on 92% of days in the last ten years.

Over that time it ranged from 2.1× in Feb 2017 to 150× in May 2025.

The median for 10 healthcare stocks of a similar size is 21.4×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.1×9.7×51.0×
202530.2×24.7×150×
202434.7×28.5×41.0×
202335.6×26.8×99.0×
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
20172.5×2.1×2.5×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

CompanyPE ratio
PLXProtalix BioTherapeutics11.1×
PDEXPro DEX15.1×
NATRNatures Sunshine Products12.0×
ELMDElectromed20.1×
UTMDUtah Medical Products22.6×
INFUInfuSystem34.0×
VMDViemed Healthcare27.2×
EMBCEmbecta4.6×
KEQUKewaunee Scientific11.9×
ICCCImmucell128×
ARVNArvinas45.6×
Peer median21.4×

Where Protalix BioTherapeutics ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.